Search alternatives:
step decrease » sizes decrease (Expand Search), teer decrease (Expand Search)
we decrease » _ decrease (Expand Search), nn decrease (Expand Search), teer decrease (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
Showing 1,081 - 1,100 results of 39,181 for search '(( 5 ((step decrease) OR (mean decrease)) ) OR ( 100 ((we decrease) OR (a decrease)) ))', query time: 1.39s Refine Results
  1. 1081
    Overtrained mice show reduced signaling capacity of DLS mGluR1/5 in response to a change in the prevailing A–O contingency.

    Overtrained mice show reduced signaling capacity of DLS mGluR1/5 in response to a change in the prevailing A–O contingency. by Vincent Paget-Blanc (21807763)

    Published 2025
    Save to List
    Saved in:
  2. 1082
    Antibody and antigen responses to Lufotrelvir vs placebo day 1–90.

    Antibody and antigen responses to Lufotrelvir vs placebo day 1–90. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  3. 1083
    Antibody and antigen responses to nMAb vs placebo day 1–90 for Sotrovimab.

    Antibody and antigen responses to nMAb vs placebo day 1–90 for Sotrovimab. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  4. 1084
    Antibody and antigen responses to nMAb vs placebo day 1–90 for Amubarvimab/ Romlusevimab.

    Antibody and antigen responses to nMAb vs placebo day 1–90 for Amubarvimab/ Romlusevimab. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  5. 1085
    Antibody and antigen responses to Ensovibep vs placebo day 1–90.

    Antibody and antigen responses to Ensovibep vs placebo day 1–90. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  6. 1086
    Long-term anti-nucleocapsid response by baseline patient characteristics.

    Long-term anti-nucleocapsid response by baseline patient characteristics. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  7. 1087
    Antibody and antigen responses by baseline anti-spike neutralizing response assay positivity.

    Antibody and antigen responses by baseline anti-spike neutralizing response assay positivity. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  8. 1088
    Baseline patient characteristics across neutralizing monoclonal antibody trials.

    Baseline patient characteristics across neutralizing monoclonal antibody trials. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  9. 1089
    Longitudinal antibody and antigen responses to treatment vs placebo day 1–90 for neutralizing monoclonal antibodies, among patients alive and with day 90 antibody and antigen measures (Sensitivity Analysis).

    Longitudinal antibody and antigen responses to treatment vs placebo day 1–90 for neutralizing monoclonal antibodies, among patients alive and with day 90 antibody and antigen measu... by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  10. 1090
    Longitudinal antibody and antigen responses to treatment vs placebo day 1–90 for nMAbs, among patients alive and with day 90 antibody and antigen measures (Sensitivity Analysis).

    Longitudinal antibody and antigen responses to treatment vs placebo day 1–90 for nMAbs, among patients alive and with day 90 antibody and antigen measures (Sensitivity Analysis). by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  11. 1091
    Antibody and antigen responses to nMAb vs placebo day 1–90 for Tixagevimab/ Cilgavimab.

    Antibody and antigen responses to nMAb vs placebo day 1–90 for Tixagevimab/ Cilgavimab. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  12. 1092
    Quantitative antibody and antigen responses to nMAb vs placebo day 1-90: Pooled analysis of neutralizing monoclonal antibodies.

    Quantitative antibody and antigen responses to nMAb vs placebo day 1-90: Pooled analysis of neutralizing monoclonal antibodies. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  13. 1093
    Study Flow Diagram.

    Study Flow Diagram. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  14. 1094
    Antibody and antigen responses to nMAb vs placebo day 1–90 for Bamlanivimab.

    Antibody and antigen responses to nMAb vs placebo day 1–90 for Bamlanivimab. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  15. 1095
    Antibody and antigen responses after treatment with nMAb vs placebo, day 1-90 (pooled nMAb treatments).

    Antibody and antigen responses after treatment with nMAb vs placebo, day 1-90 (pooled nMAb treatments). by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  16. 1096
    Overview of the six original ACTIV-3/TICO trials.

    Overview of the six original ACTIV-3/TICO trials. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  17. 1097
    Table_1_S100A8 and S100A9 Promote Apoptosis of Chronic Eosinophilic Leukemia Cells.DOCX

    Table_1_S100A8 and S100A9 Promote Apoptosis of Chronic Eosinophilic Leukemia Cells.DOCX by Ji-Sook Lee (632672)

    Published 2020
    “…The surface TLR4 expression increased after exposure to S100A8 and S100A9 although total TLR4 expression decreased. …”
    Save to List
    Saved in:
  18. 1098
    Table_2_S100A8 and S100A9 Promote Apoptosis of Chronic Eosinophilic Leukemia Cells.DOCX

    Table_2_S100A8 and S100A9 Promote Apoptosis of Chronic Eosinophilic Leukemia Cells.DOCX by Ji-Sook Lee (632672)

    Published 2020
    “…The surface TLR4 expression increased after exposure to S100A8 and S100A9 although total TLR4 expression decreased. …”
    Save to List
    Saved in:
  19. 1099
    Presentation_1_S100A8 and S100A9 Promote Apoptosis of Chronic Eosinophilic Leukemia Cells.PPT

    Presentation_1_S100A8 and S100A9 Promote Apoptosis of Chronic Eosinophilic Leukemia Cells.PPT by Ji-Sook Lee (632672)

    Published 2020
    “…The surface TLR4 expression increased after exposure to S100A8 and S100A9 although total TLR4 expression decreased. …”
    Save to List
    Saved in:
  20. 1100
    Mean score and proportion of selected items among women gave birth in Hossana town administration, southern Ethiopia, 2018.

    Mean score and proportion of selected items among women gave birth in Hossana town administration, southern Ethiopia, 2018. by Getachew Ossabo Babore (10788843)

    Published 2021
    Save to List
    Saved in:

Search Tools: